Dynavax Technologies (DVAX) Expected to Announce Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) is projected to issue its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Dynavax Technologies to post earnings of $0.08 per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $15.50 on Thursday. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. Dynavax Technologies has a 52-week low of $9.20 and a 52-week high of $15.73. The company has a market capitalization of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The company has a 50 day moving average of $14.21 and a 200 day moving average of $11.75.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $24.33.

Insider Activity

In other Dynavax Technologies news, COO David F. Novack sold 114,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the sale, the chief operating officer owned 63,344 shares in the company, valued at approximately $990,700.16. The trade was a 64.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC purchased a new stake in Dynavax Technologies in the 4th quarter valued at $43,000. Northwestern Mutual Wealth Management Co. increased its stake in Dynavax Technologies by 3,193.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,129 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 3,034 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth about $162,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Dynavax Technologies during the third quarter worth about $109,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.